Neurotransmitters: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 46: | Line 46: | ||
*[[Dopamine receptor|Dopamine receptors 1 page]] | *[[Dopamine receptor|Dopamine receptors 1 page]] | ||
*[[Dopamine Receptors|Dopamine receptors 2 page]] | *[[Dopamine Receptors|Dopamine receptors 2 page]] | ||
===Agonists=== | |||
*Amphetamine<ref>Jones S, Kornblum JL, Kauer JA (August 2000). "Amphetamine blocks long-term synaptic depression in the ventral tegmental area". J. Neurosci. 20 (15): 5575–80. PMID 10908593. http://www.jneurosci.org/cgi/pmidlookup?view=long&pmid=10908593.</ref> | |||
*Methamphetamine<ref>Cruickshank, CC.; Dyer, KR. (Jul 2009). "A review of the clinical pharmacology of methamphetamine.". Addiction 104 (7): 1085–99. doi:10.1111/j.1360-0443.2009.02564.x. PMID 19426289.</ref> | |||
===Antagonists=== | |||
*Clebopride<ref>Cuena Boy R, Maciá Martínez MA (1998). "[Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]" (in Spanish). Atencion Primaria 21 (5): 289–95. PMID 9608114. Free full text</ref> | |||
*Nafadotride<ref>Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 agonist. Nature. 1999;400:371–375.</ref> | |||
==Parkinson's disease== | ==Parkinson's disease== | ||
DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']'''<ref name="hadjiiconstantinou">PMID:1904055 </ref>, the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of [http://en.wikipedia.org/wiki/alpha-synuclein ''alpha-synuclein''] containing [http://en.wikipedia.org/wiki/Lewy_body ''Lewy bodies'']. | DOPA decarboxylase is responsible for the synthesis of '''[http://en.wikipedia.org/wiki/Dopamine ''dopamine'']''' and [http://en.wikipedia.org/wiki/Serotoninn ''serotonin''] from '''[http://en.wikipedia.org/wiki/L-dopa ''L-DOPA'']''' and [http://en.wikipedia.org/wiki/L-5-Hydroxytryptophan ''L-5-hydroxytryptophan''], respectively. It is highly stereospecific, yet relatively nonspecific in terms of substrate, making it a somewhat uninteresting enzyme to study. Although it is not typically a rate-determining step of dopamine synthesis, the decarboxylation of L-DOPA to dopamine by DDC is the controlling step for individuals with '''[http://en.wikipedia.org/wiki/Parkinson%27s_disease ''Parkinson's disease'']'''<ref name="hadjiiconstantinou">PMID:1904055 </ref>, the second most common neurodegenerative disorder, occuring in 1% of the population over the age of 65. The loss of dopaminergic neurons is the main cause of cognitive impairment and tremors observed in patients with the disease. The hallmark of the disease is the formation of [http://en.wikipedia.org/wiki/alpha-synuclein ''alpha-synuclein''] containing [http://en.wikipedia.org/wiki/Lewy_body ''Lewy bodies'']. | ||
